close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.9500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PharmaCyte Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
From PharmaCyte Biotech
Via Business Wire
News headline image
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The company's market cap stands at $37.0 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
News headline image
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Updates Status Of Investigational New Drug Application For Pancreatic Cancer Candidate ↗
PharmaCyte Biotech Inc (NASDAQ: PMCB) updated its activities to lift the FDA's clinical hold on PharmaCyte's treatment for locally advanced, inoperable... 
Via Benzinga
News headline image
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Epizyme (NASDAQ:EPZM) shares incr... 
Via Benzinga
News headline image
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 ↗
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
News headline image
64 Biggest Movers From Yesterday ↗
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Bio-Path Holdings (NASDAQ:BPTH) shares moved upwards by 9.69% to $5.43 during Wednesday's pre-market session. The company's market cap stands at $37.7... 
Via Benzinga
News headline image
60 Biggest Movers From Yesterday ↗
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the... 
Via Benzinga
News headline image
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
From PharmaCyte Biotech, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today